Novo Nordisk NVO announced that it has submitted a regulatory filing seeking label expansion for a higher dose of its ...

New research suggests that drugs like Ozempic and Wegovy might trigger more than just a slimmer waistline. Many users have ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, Novo Nordisk said.

Novo Nordisk cut Wegovy prices by up to 37 per cent across different doses to compete with rival drug Mounjaro from Eli Lilly ...

The current health news briefs highlight various shifts in the industry, including the potential of GLP-1s for Alzheimer's ...

With the holiday shopping season officially under way, another wave of retailers will offer Wall Street updates on quarterly ...

Current health news highlights include Novo Nordisk's Alzheimer's trials with GLP-1s, Agilent's strong revenue driven by lab ...

Data from the Evoke trials suggests that GLP-1 drugs that treat type 2 diabetes do not have a significant effect on Alzheimer ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.